Investitionsthese
Corundum Systems Biology invests in ventures that leverage systems biology to create dynamic, data-rich, and clinically impactful health solutions. The firm focuses on moving beyond reductionist approaches to enable adaptive, real-world biological context-driven healthcare that prioritizes prevention, early diagnosis, and personalized treatment.
Investitionsphase
Early-stage
Bevorzugte Reifephase für die erste Finanzierung.
Sektoren & Themen
Systems biology, data-driven healthcare, adaptive and personalized well-being solutions
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Ticketgröße
k.A.
Standard-Finanzierungsbetrag pro Runde.
Outreach & Dossier-Analysen
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
Investment Team (18)
A
Ami Suzuki
GA and HR Associate
C
Chieko Mori
Chief Business Development Officer
E
Eran Segal
Advisor
H
Henry Haiser
Operating Partner
H
Hidehiko Otake
CEO
J
Jessica Schneider
Chief Scientific Officer
K
Kenji Takeda
Auditor
N
Nakaba Kinoue
Business Development Manager
R
Rieka Chijiiwa
Innovation Associate
R
Rotem Gura Sadovsky
Head of Data Strategy
R
Ryota M. Suyama
Investment Associate
S
Satoshi Wakuya
Corporate Planning Director
S
Shunsuke Nagao
CFO
S
Sou Miyake
Head of Venture Investment
Y
Yasunobu Tanaka
Representative for OIST Programs
Y
Yasushi Yamamoto
Executive Director
Y
Yumiko Hirayama
HPP Manager
Y
Yun-Gi Kim
Advisor